Anti-malarial drug shows promise in treating Covid-19
Japanese scientists suggest mefloquine culd be used to fight Covid-19
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.As governments around the world race to vaccinate their populations, scientists in Japan are exploring innovative ways of using existing medicines to treat Covid-19 patients.
In a breakthrough study, a team of Japanese scientists from leading universities and research institutions have discovered an anti-malarial drug, mefloquine — a derivative of hydrochloroquine — as an effective cure against SARS-CoV-2 - a novel severe acute respiratory syndrome coronavirus.
The scientists also mathematically modelled the effectiveness of mefloquine to predict its potential use if applied to treat Covid-19. They calculated that mefloquine could reduce the overall viral load in affected patients to under seven per cent and shorten the time taken to eliminate the virus to 6.1 days.
This study is expected to undergo clinical trials.
Some approved drugs, such as hydroxychloroquine, lopinavir, and interferon, have already been put to clinical use against SARS-CoV-2 without establishing their clinical efficacy.
Only remdesivir, which was developed to treat Hepatitis C, has been approved for clinical use against severe Covid-19, although its effectiveness is still being challenged.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments